Small cell lung cancer; Valproate; HDAC; Chemotherapy; Mice
Abstract :
[en] Prognosis of small cell lung carcinoma (SCLC) is particularly poor, less than 5% of patients with extensive stage being alive after two years.We hypothesized that SCLC chemotherapy could be improved by using histone deacetylase (HDAC) inhibitors based on their ability to interfere with lysine acetylation and to alter gene expression. The goal of this study was to evaluate the anticancer efficacy of a HDAC inhibitor (valproate: VPA) on SCLC cells in combination with the standard chemotherapeutic first-line regimen (cisplatin + etoposide). We show that VPA induces apoptosis of small cell lung cancer cell lines and improves efficacy of cisplatin combined with etoposide. Both mitochondrial and death receptor pathways are involved in VPA-induced apoptosis. As expected for an HDAC inhibitor, VPA hyperacetylates histone H3. The mechanism of VPA pro-apoptotic activity involves induction of p21, inhibition of Bcl-xL, cleavage of Bid and phosphorylation of Erk and H2AX. In the presence of VPA, Bax is translocated from the cytoplasm to the mitochondria and cleaved in an 18 kDa isoform. Cytochrome c is released from the mitochondria into the cytosol. Transcriptomic analyses by microarray show that VPA modulates transcription of genes (Na+/ K+ ATPase, Bcl-xL) involved in chemoresistance to cisplatin and etoposide. Finally, the efficacy of VPA combined with cisplatin and etoposide is supported by preclinical models of SCLC cells engrafted into SCID mice. Together, these data demonstrate that VPA augments anticancer activity of cisplatin and etoposide, two components of the standard first-line chemotherapy of small cell lung cancer.
Disciplines :
Oncology
Author, co-author :
Hubaux, Roland
Vandermeers, Fabian ; Université de Liège - ULiège > Département des sciences cliniques > Labo de biologie des tumeurs et du développement
Jackman D.M., and Johnson B.E. Small-cell lung cancer. Lancet 366 (2005) 1385-1396
Hoffman P.C., Mauer A.M., and Vokes E.E. Lung cancer. Lancet 355 (2000) 479-485
Govindan R., Page N., Morgensztern D., et al. Changing epidemiology of small-cell lung cancer in the United States over the last 30 years: analysis of the surveillance, epidemiologic, and end results database. J Clin Oncol 24 (2006) 4539-4544
Ferraldeschi R., Baka S., Jyoti B., et al. Modern management of small-cell lung cancer. Drugs 67 (2007) 2135-2152
Amarasena I.U., Walters J.A., Wood-Baker R., and Fong K. Platinum versus non-platinum chemotherapy regimens for small cell lung cancer. Cochrane Database Syst Rev (2008) CD006849
Simon G.R., and Wagner H. Small cell lung cancer. Chest 123 (2003) 259S-271S
Treatment of small cell lung cancer: extensive diseases. Guidelines of clinical practice made by the European Lung Cancer Working Party. Rev Med Brux 2008;29:455-70.
Mascaux C., Paesmans M., Berghmans T., et al. A systematic review of the role of etoposide and cisplatin in the chemotherapy of small cell lung cancer with methodology assessment and meta-analysis. Lung Cancer 30 (2000) 23-36
von Pawel J., Schiller J.H., Shepherd F.A., et al. Topotecan versus cyclophosphamide, doxorubicin, and vincristine for the treatment of recurrent small-cell lung cancer. J Clin Oncol 17 (1999) 658-667
Baylin S.B., and Ohm J.E. Epigenetic gene silencing in cancer - a mechanism for early oncogenic pathway addiction?. Nat Rev Cancer 6 (2006) 107-116
Gronbaek K., Treppendahl M., Asmar F., and Guldberg P. Epigenetic changes in cancer as potential targets for prophylaxis and maintenance therapy. Basic Clin Pharmacol Toxicol 103 (2008) 389-396
Helmbold P., Lahtz C., Herpel E., et al. Frequent hypermethylation of RASSF1A tumour suppressor gene promoter and presence of Merkel cell polyomavirus in small cell lung cancer. Eur J Cancer 45 (2009) 2207-2211
Platta C.S., Greenblatt D.Y., Kunnimalaiyaan M., and Chen H. The HDAC inhibitor trichostatin A inhibits growth of small cell lung cancer cells. J Surg Res 142 (2007) 219-226
Platta C.S., Greenblatt D.Y., Kunnimalaiyaan M., and Chen H. Valproic acid induces Notch1 signaling in small cell lung cancer cells. J Surg Res 148 (2008) 31-37
Tsurutani J., Soda H., Oka M., et al. Antiproliferative effects of the histone deacetylase inhibitor FR901228 on small-cell lung cancer lines and drug-resistant sublines. Int J Cancer 104 (2003) 238-242
Achachi A., Florins A., Gillet N., et al. Valproate activates bovine leukemia virus gene expression, triggers apoptosis, and induces leukemia/lymphoma regression in vivo. Proc Natl Acad Sci USA 102 (2005) 10309-10314
Bouzar A.B., Boxus M., Defoiche J., et al. Valproate synergizes with purine nucleoside analogues to induce apoptosis of B-chronic lymphocytic leukaemia cells. Br J Haematol 144 (2009) 41-52
Crisanti M.C., Wallace A.F., Kapoor V., et al. The HDAC inhibitor panobinostat (LBH589) inhibits mesothelioma and lung cancer cells in vitro and in vivo with particular efficacy for small cell lung cancer. Mol Cancer Ther 8 (2009) 2221-2231
Vandermeers F., Hubert P., Delvenne P., et al. Valproate, in combination with pemetrexed and cisplatin, provides additional efficacy to the treatment of malignant mesothelioma. Clin Cancer Res 15 (2009) 2818-2828
Brodie M.J., and Dichter M.A. Antiepileptic drugs. N Engl J Med 334 (1996) 168-175
Chapman A., Keane P.E., Meldrum B.S., et al. Mechanism of anticonvulsant action of valproate. Prog Neurobiol 19 (1982) 315-359
DeVane C.L. Pharmacokinetics, drug interactions, and tolerability of valproate. Psychopharmacol Bull 37 Suppl. 2 (2003) 25-42
Bjerkedal T., Czeizel A., Goujard J., et al. Valproic acid and spina bifida. Lancet 2 (1982) 1096
Cinatl Jr. J., Cinatl J., Scholz M., et al. Antitumor activity of sodium valproate in cultures of human neuroblastoma cells. Anticancer Drugs 7 (1996) 766-773
Gurvich N., Tsygankova O.M., Meinkoth J.L., and Klein P.S. Histone deacetylase is a target of valproic acid-mediated cellular differentiation. Cancer Res 64 (2004) 1079-1086
Phiel C.J., Zhang F., Huang E.Y., et al. Histone deacetylase is a direct target of valproic acid, a potent anticonvulsant, mood stabilizer, and teratogen. J Biol Chem 276 (2001) 36734-36741
Roth S.Y., Denu J.M., and Allis C.D. Histone acetyltransferases. Annu Rev Biochem 70 (2001) 81-120
Wolffe A.P., and Hayes J.J. Chromatin disruption and modification. Nucl Acids Res 27 (1999) 711-720
Iizuka M., and Smith M.M. Functional consequences of histone modifications. Curr Opin Genet Dev 13 (2003) 154-160
Gottlicher M., Minucci S., Zhu P., et al. Valproic acid defines a novel class of HDAC inhibitors inducing differentiation of transformed cells. EMBO J 20 (2001) 6969-6978
Hrzenjak A., Moinfar F., Kremser M.L., et al. Valproate inhibition of histone deacetylase 2 affects differentiation and decreases proliferation of endometrial stromal sarcoma cells. Mol Cancer Ther 5 (2006) 2203-2210
Li X.N., Shu Q., Su J.M., et al. Valproic acid induces growth arrest, apoptosis, and senescence in medulloblastomas by increasing histone hyperacetylation and regulating expression of p21Cip1, CDK4, and CMYC. Mol Cancer Ther 4 (2005) 1912-1922
Lin C.T., Lai H.C., Lee H.Y., et al. Valproic acid resensitizes cisplatin-resistant ovarian cancer cells. Cancer Sci 99 (2008) 1218-1226
Ziauddin M.F., Yeow W.S., Maxhimer J.B., et al. Valproic acid, an antiepileptic drug with histone deacetylase inhibitory activity, potentiates the cytotoxic effect of Apo2L/TRAIL on cultured thoracic cancer cells through mitochondria-dependent caspase activation. Neoplasia 8 (2006) 446-457
Duenas-Gonzalez A., Candelaria M., Perez-Plascencia C., et al. Valproic acid as epigenetic cancer drug: preclinical, clinical and transcriptional effects on solid tumors. Cancer Treat Rev 34 (2008) 206-222
Spiller H.A., Krenzelok E.P., Klein-Schwartz W., et al. Multicenter case series of valproic acid ingestion: serum concentrations and toxicity. J Toxicol Clin Toxicol 38 (2000) 755-760
Stewart DJ. Tumor and host factors that may limit efficacy of chemotherapy in non-small and small cell lung cancer. Crit Rev Oncol/Hematol 2009; in press. doi:10.1016/j.critrevonc.2009.11.006.
Bunn Jr. P.A., Soriano A., Johnson G., and Heasley L. New therapeutic strategies for lung cancer: biology and molecular biology come of age. Chest 117 (2000) 163S-168S
Doi S., Soda H., Oka M., et al. The histone deacetylase inhibitor FR901228 induces caspase-dependent apoptosis via the mitochondrial pathway in small cell lung cancer cells. Mol Cancer Ther 3 (2004) 1397-1402
Li H., Zhu H., Xu C.J., and Yuan J. Cleavage of BID by caspase 8 mediates the mitochondrial damage in the Fas pathway of apoptosis. Cell 94 (1998) 491-501
Luo X., Budihardjo I., Zou H., et al. Bid, a Bcl2 interacting protein, mediates cytochrome c release from mitochondria in response to activation of cell surface death receptors. Cell 94 (1998) 481-490
Wang X. The expanding role of mitochondria in apoptosis. Genes Dev 15 (2001) 2922-2933
Billen L.P., Shamas-Din A., and Andrews D.W. Bid: a Bax-like BH3 protein. Oncogene 27S 1 (2008) S93-S104
Kumar B.S., Huang J., Persaud S., and Basu A. Down-regulation of Bcl-2 is associated with cisplatin resistance in human small cell lung cancer H69 cells. Mol Cancer Ther 3 (2004) 327-334
Ming L., Wang P., Bank A., et al. PUMA Dissociates Bax and Bcl-X(L) to induce apoptosis in colon cancer cells. J Biol Chem 281 (2006) 16034-16042
Yu J., Wang Z., Kinzler K.W., et al. PUMA mediates the apoptotic response to p53 in colorectal cancer cells. Proc Natl Acad Sci USA 100 (2003) 1931-1936
Cao X., Deng X., and May W.S. Cleavage of Bax to p18 Bax accelerates stress-induced apoptosis, and a cathepsin-like protease may rapidly degrade p18 Bax. Blood 102 (2003) 2605-2614
Choi W.S., Lee E.H., Chung C.W., et al. Cleavage of Bax is mediated by caspase-dependent or -independent calpain activation in dopaminergic neuronal cells: protective role of Bcl-2. J Neurochem 77 (2001) 1531-1541
Gao G., and Dou Q.P. N-terminal cleavage of bax by calpain generates a potent proapoptotic 18-kDa fragment that promotes bcl-2-independent cytochrome C release and apoptotic cell death. J Cell Biochem 80 (2000) 53-72
Wood D.E., Thomas A., Devi L.A., et al. Bax cleavage is mediated by calpain during drug-induced apoptosis. Oncogene 17 (1998) 1069-1078
Dokmanovic M., Clarke C., and Marks P.A. Histone deacetylase inhibitors: overview and perspectives. Mol Cancer Res 5 (2007) 981-989
Lindemann R.K., Gabrielli B., and Johnstone R.W. Histone-deacetylase inhibitors for the treatment of cancer. Cell Cycle 3 (2004) 779-788
Kim M.S., Blake M., Baek J.H., et al. Inhibition of histone deacetylase increases cytotoxicity to anticancer drugs targeting DNA. Cancer Res 63 (2003) 7291-7300
Tsai S.C., Valkov N., Yang W.M., et al. Histone deacetylase interacts directly with DNA topoisomerase II. Nat Genet 26 (2000) 349-353
Cohen H.Y., Lavu S., Bitterman K.J., et al. Acetylation of the C terminus of Ku70 by CBP and PCAF controls Bax-mediated apoptosis. Mol Cell 13 (2004) 627-638
Catalano M.G., Fortunati N., Pugliese M., et al. Valproic acid, a histone deacetylase inhibitor, enhances sensitivity to doxorubicin in anaplastic thyroid cancer cells. J Endocrinol 191 (2006) 465-472
Marchion D.C., Bicaku E., Daud A.I., et al. Valproic acid alters chromatin structure by regulation of chromatin modulation proteins. Cancer Res 65 (2005) 3815-3822
Hann C.L., and Rudin C.M. Management of small-cell lung cancer: incremental changes but hope for the future. Oncology 22 (2008) 1486-1492
Lara Jr. P.N., Natale R., Crowley J., et al. Phase III trial of irinotecan/cisplatin compared with etoposide/cisplatin in extensive-stage small-cell lung cancer: clinical and pharmacogenomic results from SWOG S0124. J Clin Oncol 27 (2009) 2530-2535
Munster P., Marchion D., Bicaku E., et al. Clinical and biological effects of valproic acid as a histone deacetylase inhibitor on tumor and surrogate tissues: phase I/II trial of valproic acid and epirubicin/FEC. Clin Cancer Res 15 (2009) 2488-2496
Munster P., Marchion D., Bicaku E., et al. Phase I trial of histone deacetylase inhibition by valproic acid followed by the topoisomerase II inhibitor epirubicin in advanced solid tumors: a clinical and translational study. J Clin Oncol 25 (2007) 979-985